

Yong-Qing Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1600466/publications.pdf>

Version: 2024-02-01

21
papers

276
citations

1163117

8
h-index

940533

16
g-index

22
all docs

22
docs citations

22
times ranked

347
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the quantification of regadenoson in human plasma and its pharmacokinetic application. <i>Journal of Separation Science</i> , 2022, , .	2.5	1
2	Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. <i>Archives of Toxicology</i> , 2022, 96, 1075-1087.	4.2	5
3	LC-MS/MS methods to quantify HCP002 in human plasma and urine: applications in a pharmacokinetic study. <i>Bioanalysis</i> , 2022, 14, 307-316.	1.5	0
4	LC-MS/MS methods for determination of unstable pivmecillinam and mecillinam in acidified human plasma: Application to a pharmacokinetic study. <i>Journal of Separation Science</i> , 2022, 45, 2543-2554.	2.5	0
5	Simultaneous Determination of Cortisol and 6 ¹² -Hydroxycortisol in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry. <i>Journal of Chromatographic Science</i> , 2022, , .	1.4	0
6	Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies. <i>Xenobiotica</i> , 2021, 51, 1199-1206.	1.1	1
7	Corosolic acid and its structural analogs: A systematic review of their biological activities and underlying mechanism of action. <i>Phytomedicine</i> , 2021, 91, 153696.	5.3	25
8	Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. <i>Pharmacological Research</i> , 2020, 152, 104606.	7.1	28
9	Simultaneous enantioselective determination of omeprazole, rabeprazole, lansoprazole, and pantoprazole enantiomers in human plasma by chiral liquid chromatography-tandem mass spectrometry. <i>Journal of Separation Science</i> , 2020, 43, 3183-3196.	2.5	9
10	Development and validation an LC-MS/MS method to quantify (+)-borneol in rat plasma: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1109, 121-127.	2.3	5
11	Safety, pharmacokinetics, and pharmacodynamics of S-($\hat{\sim}$)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 257-265.	1.9	2
12	Stereoselective pharmacokinetics of (R)-(+)- and (S)-($\hat{\sim}$)-rabeprazole in human using chiral LC-MS/MS after administration of rabeprazole sodium enteric-coated tablet. <i>Chirality</i> , 2018, 30, 1277-1286.	2.6	5
13	Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 547-554.	1.9	3
14	A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. <i>Advances in Therapy</i> , 2017, 34, 1070-1086.	2.9	98
15	Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors. <i>Current Drug Metabolism</i> , 2016, 17, 692-702.	1.2	14
16	Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors. <i>Current Drug Metabolism</i> , 2016, 17, 692-702.	1.2	3
17	Effect of <i>Toona microcarpa</i> Harms Leaf Extract on the Coagulation System. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	11
18	Molecular Evolution of the Vertebrate FK506 Binding Protein 25. <i>International Journal of Genomics</i> , 2014, 2014, 1-9.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Direct thrombin inhibitors: Patents 2002â€“2012 (Review). <i>Molecular Medicine Reports</i> , 2014, 9, 1506-1514.	2.4	20
20	H ⁺ /K ⁺ -ATPase inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2013, 23, 99-111.	5.0	32
21	Therapeutic effects of CPU 86017 on acute and chronic congestive cardiac failure mediated by reducing ET-1/NOS and oxidative stress in rats. <i>Drug Development Research</i> , 2004, 63, 22-32.	2.9	12